The results of an open comparative study in parallel groups of the efficacy and safety of the Refnot® (tumor necrosis factor - thymosin - 1 alpha recombinant) drug in the treatment of disseminated triple negative breast cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.